Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
Oric Pharmaceuticals Inc (ORIC) - Net Assets
Latest net assets as of September 2025: $406.92 Million USD
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has net assets worth $406.92 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($431.19 Million) and total liabilities ($24.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $406.92 Million |
| % of Total Assets | 94.37% |
| Annual Growth Rate | 37.83% |
| 5-Year Change | -16.1% |
| 10-Year Change | N/A |
| Growth Volatility | 169.7 |
Oric Pharmaceuticals Inc - Net Assets Trend (2017–2024)
This chart illustrates how Oric Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oric Pharmaceuticals Inc (2017–2024)
The table below shows the annual net assets of Oric Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $243.12 Million | +8.49% |
| 2023-12-31 | $224.09 Million | +0.78% |
| 2022-12-31 | $222.35 Million | -18.55% |
| 2021-12-31 | $272.98 Million | -5.80% |
| 2020-12-31 | $289.78 Million | +229.39% |
| 2019-12-31 | $87.97 Million | +236.55% |
| 2018-12-31 | $-64.43 Million | -350.43% |
| 2017-12-31 | $25.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oric Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51833000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $379.00K | 0.16% |
| Other Components | $805.51 Million | 331.32% |
| Total Equity | $243.12 Million | 100.00% |
Oric Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanxi Zhangze Electric Power Co Ltd
SHE:000767
|
$768.72 Million |
|
Omeros Corporation
NASDAQ:OMER
|
$768.96 Million |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
$769.08 Million |
|
Purecycle Technologies Holdings Corp
NASDAQ:PCT
|
$769.08 Million |
|
MASTERBRAND INC. DL-001
F:D55
|
$768.54 Million |
|
Amalgamated Bank
NASDAQ:AMAL
|
$768.44 Million |
|
Chongqing Taiji Industry Group Co Ltd
SHG:600129
|
$768.31 Million |
|
Servyou Software Group Co Ltd
SHG:603171
|
$768.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oric Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 224,088,000 to 243,122,000, a change of 19,034,000 (8.5%).
- Net loss of 127,847,000 reduced equity.
- New share issuances of 125,000,000 increased equity.
- Other comprehensive income increased equity by 121,000.
- Other factors increased equity by 21,760,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-127.85 Million | -52.59% |
| Share Issuances | $125.00 Million | +51.41% |
| Other Comprehensive Income | $121.00K | +0.05% |
| Other Changes | $21.76 Million | +8.95% |
| Total Change | $- | 8.49% |
Book Value vs Market Value Analysis
This analysis compares Oric Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.66x to 3.46x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $18.24 | $12.07 | x |
| 2018-12-31 | $-37.15 | $12.07 | x |
| 2019-12-31 | $2.94 | $12.07 | x |
| 2020-12-31 | $13.21 | $12.07 | x |
| 2021-12-31 | $7.19 | $12.07 | x |
| 2022-12-31 | $5.61 | $12.07 | x |
| 2023-12-31 | $4.36 | $12.07 | x |
| 2024-12-31 | $3.49 | $12.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oric Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-52.59%) is below the historical average (-38.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -85.63% | 0.00% | 0.00x | 1.17x | $-24.60 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.92 Million |
| 2019 | -30.56% | 0.00% | 0.00x | 1.07x | $-35.68 Million |
| 2020 | -25.43% | 0.00% | 0.00x | 1.03x | $-102.68 Million |
| 2021 | -28.46% | 0.00% | 0.00x | 1.09x | $-104.97 Million |
| 2022 | -40.08% | 0.00% | 0.00x | 1.13x | $-111.36 Million |
| 2023 | -44.94% | 0.00% | 0.00x | 1.14x | $-123.11 Million |
| 2024 | -52.59% | 0.00% | 0.00x | 1.13x | $-152.16 Million |
Industry Comparison
This section compares Oric Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc (ORIC) | $406.92 Million | -85.63% | 0.06x | $768.58 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |